Based on the Axogen Inc stock forecast from 2 analysts, the average analyst target price for Axogen Inc is USD 24.00 over the next 12 months. Axogen Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Axogen Inc is Slightly Bearish, which is based on 4 positive signals and 5 negative signals. At the last closing, Axogen Inc’s stock price was USD 17.45. Axogen Inc’s stock price has changed by -4.17% over the past week, -1.91% over the past month and +112.03% over the last year.
No recent analyst target price found for Axogen Inc
No recent average analyst rating found for Axogen Inc
Company Overview Axogen Inc
Axogen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. Axogen, Inc. is headquartered in Alachua, Florida. Read Less
Axogen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging sever...Read More
Frequently Asked Questions About Axogen Inc (AXGN) Stock
Based on ratings from 2 analysts Axogen Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 3 buy, sell and hold ratings.
Unfortunately we do not have enough data on AXGN's stock to indicate if its a good dividend stock.
Based on targets from 2 analysts, the average taret price for AXGN is USD 24.00 over the next 12 months. The maximum analyst target price is USD 26 while the minimum anlayst target price is USD 22.
Unfortunately we do not have enough data on AXGN's stock to indicate if its overvalued.
The last closing price of AXGN's stock was USD 17.45.
The most recent market capitalization for AXGN is USD 0.80B.
Based on targets from 2 analysts, the average taret price for AXGN is projected at USD 24.00 over the next 12 months.
This means that AXGN's stock price may go up by +37.54% over the next 12 months.
We can't find any ETFs which contains Axogen Inc's stock.
As per our most recent records Axogen Inc has 426 Employees.
Axogen Inc's registered address is 13631 Progress Boulevard, Alachua, FL, United States, 32615.
You can get more information about it from Axogen Inc's website at https://www.axogeninc.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Axogen Inc (AXGN) Stock
Based on ratings from 2 analysts Axogen Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 3 buy, sell and hold ratings.
Unfortunately we do not have enough data on AXGN's stock to indicate if its a good dividend stock.
Based on targets from 2 analysts, the average taret price for AXGN is USD 24.00 over the next 12 months. The maximum analyst target price is USD 26 while the minimum anlayst target price is USD 22.
Unfortunately we do not have enough data on AXGN's stock to indicate if its overvalued.
The last closing price of AXGN's stock was USD 17.45.
The most recent market capitalization for AXGN is USD 0.80B.
Based on targets from 2 analysts, the average taret price for AXGN is projected at USD 24.00 over the next 12 months.
This means that AXGN's stock price may go up by +37.54% over the next 12 months.
We can't find any ETFs which contains Axogen Inc's stock.
As per our most recent records Axogen Inc has 426 Employees.
Axogen Inc's registered address is 13631 Progress Boulevard, Alachua, FL, United States, 32615.
You can get more information about it from Axogen Inc's website at https://www.axogeninc.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for AXGN !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
